Proactive Investors - Run By Investors For Investors

Vector Therapeutics using technology to try and prevent acute Leukemia relapse

Vector Therapeutics Corp CEO Daniel Teper  updates Proactive Investor's Christine Corrado at the 11th Annual Biotech Showcase in San Francisco. The New York based pharma company is focused on providing life-changing, precision-immunotherapy treatments for a variety of cancers, mainly leukemia.

 
Meet Alliance Pharma PLC, IXICO PLC, Benchmark Holdings PLC, Clinigen Group PLC and Shield Therapeutics PLC at our event, London , 24 January 2019. Register here »
View full VECTO profile View Profile

Vector Therapeutics Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use